| scholarly article | Q13442814 |
| P819 | ADS bibcode | 1995PNAS...92.1411C |
| P356 | DOI | 10.1073/PNAS.92.5.1411 |
| P932 | PMC publication ID | 42529 |
| P698 | PubMed publication ID | 7877992 |
| P5875 | ResearchGate publication ID | 15321220 |
| P50 | author | Bernard Roizman | Q4893595 |
| P2093 | author name string | G Y Gillespie | |
| R J Whitley | |||
| R Chambers | |||
| S Chatterjee | |||
| J Chou | |||
| L Soroceanu | |||
| S Andreansky | |||
| P2860 | cites work | Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery | Q33483488 |
| Replication, establishment of latency, and induced reactivation of herpes simplex virus gamma 1 34.5 deletion mutants in rodent models | Q35611914 | ||
| Differential response of human cells to deletions and stop codons in the gamma(1)34.5 gene of herpes simplex virus. | Q36638186 | ||
| The herpes simplex virus 1 gene for ICP34.5, which maps in inverted repeats, is conserved in several limited-passage isolates but not in strain 17syn+. | Q36801858 | ||
| The terminal a sequence of the herpes simplex virus genome contains the promoter of a gene located in the repeat sequences of the L component. | Q36857990 | ||
| Identification by antibody to a synthetic peptide of a protein specified by a diploid gene located in the terminal repeats of the L component of herpes simplex virus genome | Q36863560 | ||
| The gamma 1(34.5) gene of herpes simplex virus 1 precludes neuroblastoma cells from triggering total shutoff of protein synthesis characteristic of programed cell death in neuronal cells | Q36945982 | ||
| High dose radiation therapy in the treatment of malignant gliomas: Final Report | Q40285828 | ||
| Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant | Q41451279 | ||
| An experimental model of retrovirus gene therapy for malignant brain tumors | Q41543855 | ||
| Reduction and elimination of encephalitis in an experimental glioma therapy model with attenuated herpes simplex mutants that retain susceptibility to acyclovir | Q41563446 | ||
| Gene delivery to glioma cells in rat brain by grafting of a retrovirus packaging cell line | Q41716747 | ||
| Tumorigenic cell culture lines from a spontaneous VM/Dk murine astrocytoma (SMA). | Q42802372 | ||
| In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats | Q42813300 | ||
| In Vivo Gene Transfer with Retroviral Vector-Producer Cells for Treatment of Experimental Brain Tumors | Q42818740 | ||
| The effect of thymidine kinase transduction and ganciclovir therapy on tumor vasculature and growth of 9L gliomas in rats | Q42835030 | ||
| Correlates of survival and the Daumas-Duport grading system for astrocytomas | Q43439404 | ||
| Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture | Q44460699 | ||
| Characterization of herpes simplex virus strains differing in their effects on social behaviour of infected cells | Q45823697 | ||
| Acyclovir-resistant herpes simplex virus infections in patients with the acquired immunodeficiency syndrome. | Q45846461 | ||
| Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant | Q45854779 | ||
| Gene therapy of malignant brain tumors: a rat glioma line bearing the herpes simplex virus type 1-thymidine kinase gene and wild type retrovirus kills other tumor cells | Q45876121 | ||
| In vivo transfer of the human interleukin-2 gene: negative tumoricidal results in experimental brain tumors. | Q48164484 | ||
| Grading of astrocytomas. A simple and reproducible method. | Q55485939 | ||
| National survey of patterns of care for brain-tumor patients | Q57106043 | ||
| Toxicity studies of retroviral-mediated gene transfer for the treatment of brain tumors | Q70472317 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | brain tumor | Q233309 |
| P304 | page(s) | 1411-1415 | |
| P577 | publication date | 1995-02-01 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma | |
| P478 | volume | 92 |
| Q34374721 | 5-fluorouracil and gemcitabine potentiate the efficacy of oncolytic herpes viral gene therapy in the treatment of pancreatic cancer |
| Q33851852 | A herpes simplex virus type 1 gamma34.5 second-site suppressor mutant that exhibits enhanced growth in cultured glioblastoma cells is severely attenuated in animals |
| Q40800987 | A herpes simplex virus type 1 mutant deleted for gamma34.5 and LAT kills glioma cells in vitro and is inhibited for in vivo reactivation |
| Q34302130 | Activated MEK suppresses activation of PKR and enables efficient replication and in vivo oncolysis by Deltagamma(1)34.5 mutants of herpes simplex virus 1 |
| Q40125989 | An HSV-2-based oncolytic virus deleted in the PK domain of the ICP10 gene is a potent inducer of apoptotic death in tumor cells |
| Q42542383 | An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy |
| Q43934769 | Antitumor effects on human melanoma xenografts of an amplicon vector transducing the herpes thymidine kinase gene followed by ganciclovir |
| Q33816579 | Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation of intracerebral injection in nonhuman primates. |
| Q33649894 | B-myb promoter retargeting of herpes simplex virus gamma34.5 gene-mediated virulence toward tumor and cycling cells |
| Q37857659 | Clinical development directions in oncolytic viral therapy |
| Q78392743 | Comparison of safety, delivery, and efficacy of two oncolytic herpes viruses (G207 and NV1020) for peritoneal cancer |
| Q33804845 | Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant |
| Q35842604 | Conditionally replicative adenovirus for gastrointestinal cancers |
| Q45868174 | Conditionally replicative adenoviruses for cancer therapy |
| Q37660477 | Creation of drug-specific herpes simplex virus type 1 thymidine kinase mutants for gene therapy |
| Q34074791 | Current status of viral gene therapy for brain tumours |
| Q35559877 | Design and application of oncolytic HSV vectors for glioblastoma therapy |
| Q34046125 | Development of a regulatable oncolytic herpes simplex virus type 1 recombinant virus for tumor therapy |
| Q41249266 | Development of drug targeting based on recombinant expression of the chicken avidin gene |
| Q45869026 | Effect of temperature, medium composition, and cell passage on production of herpes-based viral vectors |
| Q35051285 | Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors |
| Q45411954 | Engineered herpes simplex virus expressing bacterial cytosine deaminase for experimental therapy of brain tumors |
| Q62971299 | Engineering Herpes Simplex |
| Q40146542 | Enhanced antiglioma activity of chimeric HCMV/HSV-1 oncolytic viruses |
| Q37116149 | Enhanced antitumor efficacy of a herpes simplex virus mutant isolated by genetic selection in cancer cells |
| Q40464370 | Enhanced inhibition of syngeneic murine tumors by combinatorial therapy with genetically engineered HSV-1 expressing CCL2 and IL-12. |
| Q40373406 | Enhanced therapeutic efficacy of G207 for the treatment of glioma through Musashi1 promoter retargeting of gamma34.5-mediated virulence. |
| Q42234691 | Evaluation of the Safety and Biodistribution of M032, an Attenuated HSV-1 Virus Expressing hIL-12, After Intracerebral Administration to Aotus Non-Human Primates |
| Q33720628 | Evaluation of the safety and biodistribution of M032, an attenuated herpes simplex virus type 1 expressing hIL-12, after intracerebral administration to aotus nonhuman primates |
| Q33690926 | Expression of RNA interference triggers from an oncolytic herpes simplex virus results in specific silencing in tumour cells in vitro and tumours in vivo |
| Q35673628 | Gene therapy for malignant glioma |
| Q43612836 | Gene therapy for malignant gliomas |
| Q41332176 | Gene therapy for neurologic disease: benchtop discoveries to bedside applications. 1. The bench |
| Q45890411 | Gene therapy of malignant glioma: recent advances in experimental and clinical studies |
| Q35116166 | Genetic metamorphosis of herpes simplex virus-1 into a biological therapeutic for human cancer |
| Q35126267 | Genetically Engineered Herpes Simplex Viral Vectors in the Treatment of Brain Tumors: A Review |
| Q33827571 | Genetically engineered HSV in the treatment of glioma: a review |
| Q38225874 | Glioblastoma multiforme: State of the art and future therapeutics |
| Q37787777 | HSV Recombinant Vectors for Gene Therapy |
| Q79124523 | HSV-1 therapy of primary tumors reduces the number of metastases in an immune-competent model of metastatic breast cancer |
| Q33995752 | HSV-1-based vectors for gene therapy of neurological diseases and brain tumors: part II. Vector systems and applications |
| Q38185694 | Herpes simplex viral vectors: late bloomers with big potential |
| Q36444443 | Herpes simplex virus 1 (HSV-1) for cancer treatment |
| Q33713824 | Herpes simplex virus oncolytic therapy for pediatric malignancies |
| Q34139375 | Herpes simplex viruses: is a vaccine tenable? |
| Q83017114 | Highly efficient regulation of gene expression by tetracycline in a replication-defective herpes simplex viral vector |
| Q45752750 | Histopathological responses in the CNS following inoculation with a non-neurovirulent mutant (1716) of herpes simplex virus type 1 (HSV 1): relevance for gene and cancer therapy |
| Q55475423 | Human malignant glioma therapy using anti-alpha(v)beta3 integrin agents. |
| Q30355682 | IL-12 Expressing oncolytic herpes simplex virus promotes anti-tumor activity and immunologic control of metastatic ovarian cancer in mice. |
| Q38348844 | Immune Suppression during Oncolytic Virotherapy for High-Grade Glioma; Yes or No? |
| Q35800497 | Increased efficacy of an interleukin-12-secreting herpes simplex virus in a syngeneic intracranial murine glioma model |
| Q45869133 | Infectivity enhanced, cyclooxygenase-2 promoter-based conditionally replicative adenovirus for pancreatic cancer |
| Q45889397 | Modelling the enhancement of fractionated radiotherapy by gene transfer to sensitize tumour cells to radiation |
| Q45748857 | Mutant herpes simplex virus-mediated suppression of retinoblastoma |
| Q45862524 | Nitroreductase-mediated cell ablation is very rapid and mediated by a p53-independent apoptotic pathway |
| Q27006099 | Novel delivery strategies for glioblastoma |
| Q35864136 | Novel therapies in glioblastoma |
| Q35216661 | Oncolytic herpes simplex virus for tumor therapy |
| Q35945465 | Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. |
| Q28202611 | Oncolytic herpes simplex virus vectors for cancer virotherapy |
| Q35613495 | Oncolytic herpes viruses as a potential mechanism for cancer therapy. |
| Q45745953 | Oncolytic therapy using a mutant type-1 herpes simplex virus and the role of the immune system |
| Q35852258 | Oncolytic viral therapies |
| Q35610296 | Oncolytic viruses: clinical applications as vectors for the treatment of malignant gliomas |
| Q36220799 | Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate |
| Q36644898 | Pediatric glioma stem cells: biologic strategies for oncolytic HSV virotherapy |
| Q35943736 | Preclinical evaluation of a genetically engineered herpes simplex virus expressing interleukin-12 |
| Q36546412 | Preclinical evaluation of oncolytic δγ(1)34.5 herpes simplex virus expressing interleukin-12 for therapy of breast cancer brain metastases |
| Q43873064 | Prevention of restenosis by a herpes simplex virus mutant capable of controlled long-term expression in vascular tissue in vivo |
| Q35060701 | Production of bioactive soluble interleukin-15 in complex with interleukin-15 receptor alpha from a conditionally-replicating oncolytic HSV-1 |
| Q33799437 | Pseudotyping of glycoprotein D-deficient herpes simplex virus type 1 with vesicular stomatitis virus glycoprotein G enables mutant virus attachment and entry |
| Q40268283 | Real-time intraoperative detection of breast cancer axillary lymph node metastases using a green fluorescent protein-expressing herpes virus |
| Q36288909 | Replication-competent herpes simplex vectors: design and applications |
| Q37882608 | Rethinking herpes simplex virus: the way to oncolytic agents |
| Q58598588 | Selective Editing of HSV-1 Enables IFN Induction and Viral Replication That Destruct Malignant Cells |
| Q24679781 | Selective in vitro replication of herpes simplex virus type 1 (HSV-1) ICP34.5 null mutants in primary human CNS tumours--evaluation of a potentially effective clinical therapy |
| Q35043098 | Selectively replicating viral vectors |
| Q44452117 | Sustained inhibition of experimental neointimal hyperplasia with a genetically modified herpes simplex virus |
| Q37247954 | The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors |
| Q45722305 | The herpes simplex virus (HSV) protein ICP34.5 is a virion component that forms a DNA-binding complex with proliferating cell nuclear antigen and HSV replication proteins |
| Q35888685 | The range and distribution of murine central nervous system cells infected with the gamma(1)34.5- mutant of herpes simplex virus 1. |
| Q40378381 | The role of ICP0-Null HSV-1 and interferon signaling defects in the effective treatment of breast adenocarcinoma. |
| Q45733718 | The use of a genetically engineered herpes simplex virus (R7020) with ionizing radiation for experimental hepatoma |
| Q36318160 | To replicate or not to replicate: achieving selective oncolytic virus replication in cancer cells through translational control |
| Q33905047 | Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma |
| Q34423157 | Treatment of human hepatocellular carcinoma by the oncolytic herpes simplex virus G47delta |
| Q48315993 | Up- and down-expression of the dopamine transporter by plasmid DNA transfer in the rat brain |
| Q73544938 | Use of clinically relevant human-scid-mouse models in metastasis research |
| Q45520731 | Widespread intratumoral virus distribution with fractionated injection enables local control of large human rhabdomyosarcoma xenografts by oncolytic herpes simplex viruses |
| Q55471314 | [Oncolytic viral therapy of gliomas: review of the literature] |
Search more.